With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

Equity Insider News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, April 14, 2025 /CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable stages—has dropped to just over 50% of the population. At the same time, doctors are raising alarm bells over a noticeable increase in cancer diagnoses among younger adults, especially women. With proposed funding cuts to the NIH now on the table and new estimates suggesting that drug tariffs could add $10,000 or more to treatment costs, the path forward may rely less on government programs and more on private-sector breakthroughs. So far in 2025, several oncology innovators have stepped forward with meaningful updates, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), CEL-SCI Corporation (NYSE-American:CVM), OS Therapies Incorporated (NYSE-American:OSTX), BeiGene, Ltd. (NASDAQ:ONC), and Actinium Pharmaceuticals, Inc. (NYSE-American:ATNM).